JAK inhibitors in IBD
Upadacitinib, tofacitinib and filgotinib in inflammatory bowel disease.
Key point
Tofacitinib and filgotinib are efficacious in ulcerative colitis, and upadacitinib is efficacious in both ulcerative colitis and Crohn’s disease.
From: Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease (J Gastroenterol Hepatol, 2026 Jul) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 9, 15, 15, 14, 17.
New guidelines and consensus this year
- Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's DiseaseJ Gastroenterol Hepatol2026 Jul
- [PANCCO Clinical Practice Guideline Update for the treatment of ulcerative colitis in adults]Rev Gastroenterol Peru2026 Apr-Jun
- AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's DiseaseGastroenterology2025 Dec
All papers from the last 12 months
358 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- The molecular mechanism of the adverse effects of the biological and small molecular drugs in the therapy of inflammatory skin diseases - psoriasis and atopic dermatitisAnn Med2026 DecPMID 41481132Review
- Upadacitinib effectively suppresses IL13RA2 expression in primary human intestinal fibroblasts derived from Crohn's disease tissueBiochem Pharmacol2026 NovPMID 42603621
- Development and validation of the SYSU-score for MRI-based transmural healing assessment in Crohn's disease: a dual-center studyEur Radiol2026 NovPMID 42319405
- Acneiform eruption associated with Janus kinase inhibitors in pediatric inflammatory bowel disease: Case series and clinical management guidanceJPGN Rep2026 Oct 12PMID 42865982
- Tofacitinib 20 vs 30 mg in acute severe ulcerative colitis: a double-blind randomized controlled trialJ Crohns Colitis2026 Oct 9PMID 42880720RCT
- Management of Upadacitinib-Induced Anemia in a Patient With Ulcerative ColitisAm J Ther2026 Oct 9PMID 42850716
- Differential long-term efficacy of biologic and small-molecule therapies by disease location in moderate-to-severe luminal Crohn's disease: a systematic review and network meta-analysisInflamm Bowel Dis2026 Oct 8PMID 42850680
- Hospitalized Infection Risk and Organ-specific Infection Patterns Across Advanced Therapies in Ulcerative Colitis: A Japanese Claims AnalysisIntern Med2026 Oct 8PMID 42844189
- Comments on "Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn's disease"Intest Res2026 Oct 6PMID 42838523
- Upadacitinib and upadacitinib-vedolizumab combination therapy for refractory pediatric-onset inflammatory bowel diseaseIntest Res2026 Oct 6PMID 42838520
More gastroenterology trends
All specialties →Third-space endoscopy
Peroral endoscopic myotomy and endoscopic submucosal dissection.
Potassium-competitive acid blockers
Vonoprazan and related acid suppressants.
AI in colonoscopy
Computer-aided polyp detection and characterisation during colonoscopy.
Metallic vs plastic biliary stents
Studies comparing metallic and plastic stents for biliary obstruction.
Blood and stool tests for colorectal cancer screening
Blood-based and multitarget stool tests for colorectal cancer screening.
Key point: Next-generation mt-sDNA and mt-sRNA are preferred 3-year stool options; blood-based tests should be recommended only when preferred screening tests are declined or incomplete.
Eosinophilic esophagitis
Diagnosis and newer treatments, including biologics, for eosinophilic esophagitis.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
(upadacitinib[tiab] OR tofacitinib[tiab] OR filgotinib[tiab]) AND (Crohn[tiab] OR colitis[tiab] OR "inflammatory bowel"[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.